Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04605913
Recruitment Status : Recruiting
First Posted : October 28, 2020
Last Update Posted : April 6, 2022
Sponsor:
Collaborator:
NovoCure Ltd.
Information provided by (Responsible Party):
Mayo Clinic

Brief Summary:
This is a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy in patients with metastatic pancreatic cancer.

Condition or disease Intervention/treatment Phase
Pancreas Cancer Metastatic Pancreatic Cancer Pancreatic Adenocarcinoma Metastatic Adenocarcinoma Combination Product: Modified GCN+TTF treatment Phase 1 Phase 2

Detailed Description:
GCN is predicted to be the front-line therapy for biliary and pancreatic cancer in the future given excellent results of current early clinical trials (ORR ≥ 67% in pancreatic cancer). This will change standard of care for front-line therapy in patients with stage IV pancreatic cancer. In this cohort of patients' tolerability after 6 cycles of therapy will be a challenge. Investigators hypothesize that developing a maintenance strategy with TTF+G will be cutting edge approach and can potentially transform front-line standard of care therapy in patients with stage IV pancreatic cancer. If this pilot study proves fruitful then a larger study to confirm findings can be conducted.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: The trial will compose of 2 parts with a total of 40 subjects. The 1st part would be a safety run-in phase (phase I). In this phase, 6 patients will be treated after completing screening procedures and meeting eligibility criteria. If 6 patients tolerate this dose level of GCN+TTF through the 1st cycle without defined dose limiting toxicities (DLTs) or grade 4 treatment related adverse events (TRAE), the 2nd part of the study (phase Ib portion) will commence. An additional 34 patients will be enrolled in the expansion cohort (phase Ib).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/Ib Pilot Trial, Single Arm, Open Label, of Protein-Bound Paclitaxel, Cisplatin, and Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) in Patient With Metastatic Pancreatic Adenocarcinoma
Actual Study Start Date : April 1, 2022
Estimated Primary Completion Date : April 15, 2024
Estimated Study Completion Date : April 15, 2025


Arm Intervention/treatment
Experimental: Modified GCN+TTF treatment
The trial will compose of 2 parts with a total of 40 subjects. The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1. If 6 patients tolerate the dose level of GCN+TTF through the 1st cycle without defined dose limiting toxicities (DLTs) or grade 4 treatment related adverse events (TRAE), the 2nd part of the study (phase Ib portion) will commence. An additional 34 patients will be enrolled in the expansion cohort (phase Ib).
Combination Product: Modified GCN+TTF treatment
The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered on cycle 1 day 1 and every 2 weeks thereafter and TTF will be administered daily (150kHz 18 hours/day) starting with Cycle 1 Day 1 (dose level 1). One cycle consists of 28 days including 2 chemotherapy treatments (same regimen studied in the PAXG trial: Reni BJC 2016 without capecitabine). After completing 6 cycles, patients will then transition to a maintenance phase of G administered at a dose of 1000 mg/m2 every 2 weeks and daily TTF (150 KHZ 18 hours/day) until progression of disease (POD) per RECIST v1.1.
Other Name: NovoTTF-100L(P)




Primary Outcome Measures :
  1. Determine safety of (m)-GCN+TTF [ Time Frame: 28 days ]
    To determine the safety of modified (m)-GCN+TTF in patients with recurrent and/or metastatic pancreatic cancer (met-PC) by measuring grade 4 treatment related adverse events (TRAE).


Secondary Outcome Measures :
  1. Progression-free Survival [ Time Frame: Six months ]
  2. Overall Response Rate [ Time Frame: Six months ]
    Objective responses in tumor size will be evaluated using the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1).

  3. Overall Survival [ Time Frame: Twelve months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed pancreatic adenocarcinoma or adeno-squamous carcinoma with liver metastasis.

    1. Subjects with additional sites of metastasis, except known brain metastasis, are eligible.
    2. Histologies excluded include squamous, small cell carcinoma, and acinar cell carcinoma. However, adeno-squamous histology can be enrolled.
    3. Patients who have recurrence or metastasis after surgery and adjuvant therapy do not need repeat biopsy for confirmation of recurrence if clinical suspicion is high per scans (MRI/CT scan), with and without CA 19-9 elevation, specifically if biopsy is unsafe or technically difficult.
  2. Patients with no prior lines of therapy for the treatment of stage IV metastatic disease.

    1. Patients could have had prior neoadjuvant or adjuvant chemotherapy or chemo-radiotherapy.

    i. Patients who received gemcitabine-based adjuvant chemotherapy can enroll if they progress greater than 6 months after completion of the therapy; ii. Patients who progress while on adjuvant FOLFIRINOX can enroll immediately.

  3. Male and female patients at least 18 years of age
  4. Laboratory data as specified below:

    Hematology:

    - ANC greater than 1500 cells/mm3,

    - platelet count greater than 100,000 cells/mm3, and

    - Hemoglobin greater than 8 g/dL.

    • Hepatic

      • Total bilirubin less than 1.5 X ULN;
      • alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 3 X ULN.

    For patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 6.0 X ULN and total bilirubin less than 3 x ULN.

    • Renal:

      • serum creatinine WNL or creatinine clearance greater than 50 mL/min.
  5. QT intervals: QTc less than or equal to 470 msec for men and less than or equal to 490 msec for women. (As measured by Hodges' Equation: QTc = QT + 1.75(rate-60) where QTc = corrected QT interval and rate = ventricular rate/min).
  6. Estimated life expectancy of at least 3 months
  7. ECOG Performance Status 0-1.
  8. Ability to operate the Novo TTF-100L (P) system.
  9. Patients must have measurable disease on scans per RECIST 1.1.
  10. Negative serum pregnancy test within 14 days prior to the first dose of study therapy for women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months). Sexually active WCBP and male subjects must agree to use adequate methods to avoid pregnancy (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study and for 28 days after the completion of study treatment.

Exclusion Criteria:

1. Previous front-line therapy for metastatic disease.

  1. Patients with known brain metastasis.
  2. Cardiac conduction abnormalities such as 2nd and 3rd heart-block requiring a pacemaker.
  3. Patient with cardiac or abdominal pacemakers or stimulators.
  4. Significant risk of cardiac drug toxicity due to congestive heart failure or history of myocardial infarction.
  5. Any other condition including but not limited to major co-morbidities, which in the opinion of the investigator would render the patient ineligible.
  6. Concomitant use of drugs that have black box warning of Torsades de Pointes will also be prohibited if cannot be replaced by another drug.
  7. Known sensitivity to conductive hydrogels.

10. Patients who are pregnant or breastfeeding.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04605913


Contacts
Layout table for location contacts
Contact: Cody V. Mejia, CCRP 904-953-8789 Mejia.cody@mayo.edu

Locations
Layout table for location information
United States, Florida
Mayo Clinic Recruiting
Jacksonville, Florida, United States, 32224-9980
Contact: Clinical Trials Referral Office    855-776-0015    mayocliniccancerstudies@mayo.edu   
Principal Investigator: Hani Babiker, MD         
Sponsors and Collaborators
Mayo Clinic
NovoCure Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Hani Babiker, MD Mayo Clinic
Layout table for additonal information
Responsible Party: Mayo Clinic
ClinicalTrials.gov Identifier: NCT04605913    
Other Study ID Numbers: MC210405
NCI-2022-01522 ( Other Grant/Funding Number: NCI )
First Posted: October 28, 2020    Key Record Dates
Last Update Posted: April 6, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Mayo Clinic:
GCN
TTF
Paclitaxel
Cisplatin
Gemcitabine
Tumor Treatment Fields
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases